ZNRF2 Inhibitors
Chemical inhibitors of ZNRF2 can interfere with various cellular processes by targeting different aspects of its activity. Nervonic Acid's ability to inhibit ceramide synthase can lead to a decrease in ZNRF2 substrate availability, given ZNRF2's involvement in lipid metabolism and ceramide biosynthesis. Similarly, GW4869's inhibition of neutral sphingomyelinase, an enzyme critical to sphingolipid metabolism, can diminish the functional activity of ZNRF2 by disrupting sphingolipid-mediated signaling processes. Manumycin A, which selectively inhibits Ras farnesyltransferase, can reduce ZNRF2's contribution to Ras-related pathways, thereby affecting signal transduction associated with ZNRF2. PF-429242 impacts ZNRF2 by inhibiting the S1P protease, crucial for protein trafficking, a process in which ZNRF2 is implicated. This inhibition can impair ZNRF2's role in endosomal trafficking processes.
In addition to these, MLN4924 inhibits the NEDD8 activating enzyme that affects the ubiquitin-proteasome system. As ZNRF2 is associated with ubiquitin ligase activity, the action of MLN4924 can stabilize proteins usually targeted for degradation by ZNRF2, thus counteracting its regulatory function. GSK'872, as an inhibitor of RIPK3 kinase, can prevent necroptosis signal transduction that ZNRF2 modulates, offering another avenue through which ZNRF2 activity can be inhibited. Exo1, by targeting the exocyst complex component Exo70, can disrupt ZNRF2-mediated vesicle trafficking and membrane fusion processes. Inhibitors such as KPT-9274 and EHT 1864, which target PAK4 and Rho family GTPases respectively, can lead to disruptions in cytoskeletal dynamics and cellular migration, processes where ZNRF2 plays a role. Additionally, BAY 11-7082's inhibition of IκBα phosphorylation affects NF-κB signaling, a pathway where ZNRF2 has a regulatory role. Lastly, NSC 23766 and Ciliobrevin D exert their inhibitory effects on ZNRF2 by targeting Rac1-dependent signaling and dynein function, respectively, further elucidating the breadth of cellular processes influenced by ZNRF2 activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Nervonic acid | 506-37-6 | sc-215555 sc-215555A sc-215555B | 100 mg 250 mg 500 mg | $76.00 $152.00 $300.00 | ||
Nervonic Acid, a monounsaturated fatty acid, can inhibit the activity of ceramide synthase. ZNRF2 is involved in the regulation of lipid metabolism including ceramide biosynthesis. Inhibition of ceramide synthase could reduce ZNRF2 substrate availability. | ||||||
GW4869 | 6823-69-4 | sc-218578 sc-218578A | 5 mg 25 mg | $203.00 $611.00 | 24 | |
GW4869 is an inhibitor of neutral sphingomyelinase (nSMase), an enzyme involved in sphingolipid metabolism. ZNRF2 participates in the regulation of sphingolipid-mediated signaling; thus, GW4869 inhibition of nSMase can decrease ZNRF2's functional activity. | ||||||
Manumycin A | 52665-74-4 | sc-200857 sc-200857A | 1 mg 5 mg | $219.00 $634.00 | 5 | |
Manumycin A is a selective and potent inhibitor of Ras farnesyltransferase. ZNRF2 is known to be involved in the regulation of Ras-related pathways. By inhibiting Ras function, Manumycin A can reduce the downstream signaling that requires ZNRF2 activity. | ||||||
PF-429242 | 947303-87-9 | sc-507498 | 5 mg | $176.00 | ||
PF-429242 inhibits the S1P protease, which is crucial for protein trafficking. ZNRF2 is implicated in endosomal trafficking processes, and inhibition of S1P can impair trafficking, thereby functionally inhibiting ZNRF2's role in this cellular mechanism. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
MLN4924 inhibits NEDD8 activating enzyme, affecting protein degradation pathways. ZNRF2 is associated with ubiquitin ligase activity, and inhibition of NEDD8 can lead to stabilization of proteins that ZNRF2 targets for degradation, counteracting its function. | ||||||
Exo1 | 461681-88-9 | sc-200752 sc-200752A | 10 mg 50 mg | $84.00 $297.00 | 4 | |
Exo1 is an inhibitor of the exocyst complex component Exo70, involved in vesicle trafficking. ZNRF2, through its role in membrane trafficking and fusion, relies on properly functioning exocyst components, so Exo1 inhibition can disrupt ZNRF2-mediated processes. | ||||||
EHT 1864 | 754240-09-0 | sc-361175 sc-361175A | 10 mg 50 mg | $213.00 $889.00 | 12 | |
EHT 1864 is a potent inhibitor of the Rho family of GTPases. ZNRF2 is involved in actin dynamics affected by Rho GTPases. By inhibiting Rho activity, EHT 1864 can impair the actin remodeling processes where ZNRF2 is functionally significant. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 irreversibly inhibits IκBα phosphorylation, affecting NF-κB signaling. ZNRF2 has been implicated in NF-κB pathway regulation. By blocking this pathway, BAY 11-7082 can inhibit the functional role of ZNRF2 in NF-κB-mediated cellular responses. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $151.00 $609.00 | 75 | |
NSC 23766 is an inhibitor of the Rac1 GTPase-activating protein interaction. ZNRF2 can interact with Rac1-dependent signaling pathways; thus, inhibition of Rac1 activity by NSC 23766 can result in the functional inhibition of ZNRF2 in these pathways. | ||||||
Ciliobrevin D | 1370554-01-0 | sc-507482 | 10 mg | $413.00 | ||
Ciliobrevin D is a hedgehog signaling pathway inhibitor that targets the motor protein dynein. ZNRF2 is involved in intracellular transport processes that require dynein function. Inhibition of dynein by Ciliobrevin D can thus impair ZNRF2-dependent transport. | ||||||